Following our price target changes on eight Club holdings last month, we’re updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. Eli Lilly (LLY): Club price target increasing to $380 per share from $350 While its third-quarter wasn’t the cleanest , with management lowering its full-year revenue outlook by approximately $300 million due to increased foreign exchange headwinds, we were impressed by how Lilly’s brand new type-2 diabetes drug Mounjaro outperformed even elevated expectations. With sales growth expected to surge higher if Mounjaro were to get federal regulatory approval next year to also treat obesity, we remain very bullish that the drug could become one of the best-selling of all time. Management has been investing aggressively to increase manufacturing capacity in anticipation. It’s also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer’s. Lilly is also working on a separate Alzheimer’s drug, which has shown some encouraging results. Good news for Biogen is good news for Lilly’s donanemab as both are antibodies that aim to reduce the buildup of the amyloid beta protein in the brain, which is seen with the degenerative disease. Shares of Eli Lilly trade at a significant premium to its peer group and the broader market, but we think health care is group investors are willing to pay up for thanks to its recession-resistant characteristics and limited impact from inflation. LLY has gained more than 32% in 2022, compared to the nearly 19% year-to-date decline in the S & P 500 . Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . It also provided bullish commentary around margin expansion, backed by pricing power and a lower cost structure. Halliburton has also made significant strides in cleaning up its balance sheet, putting it in a position to potentially increase cash returns to shareholders next year. Future increases to the dividend and buyback program should further improve sentiment around the stock, which has shattered the performance of the broader market with an over 72% increase in 2022. Starbucks (SBUX): Club price target increasing $100 per share from $95 The coffee retailer reported great fiscal fourth quarter earnings last week thanks to strength in North America, where same store sales grew faster than expected with better than expected margins. We think the momentum in North America will continue as management rolls out its reinvention plan, which consists of a series of what the company calls “strategic and highly targeted investments” designed to improve the operating efficiencies of its stores. Although sales in China remain depressed due to ongoing Covid-related restrictions, we still view the Chinese market as an important investment area, and any positive news flow related to a potential reopening should lead to a higher stock price. Case in point , on Friday, news that China will allow foreigners living there to get the BioNTech (BNTX)- Pfizer (PFE) Covid vaccine and hope that Beijing may be willing to ease its rolling pandemic lockdowns and restrictions pushed Starbucks shares up 8.5%. Shares of Starbucks in 2022 took a beating into their May low of under $69 but have rallied 31% since then. We started our position on Aug. 22, and then stock jumped 6.7% since then. (Jim Cramer’s Charitable Trust is long LLY, HAL and SBUX. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC
Following our price target changes on eight Club holdings last month, we’re updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks.
Source link: https://www.cnbc.com/2022/11/08/were-increasing-price-targets-on-3-of-our-stocks-including-2-crushing-the-boarder-market.html